Prominent target kinases for PCa therapy include vascular endothelial growth factor receptor (VEGFR), breakpoint cluster region-Abelson tyrosine kinase (BCR-ABL), phosphoinositide 3-kinase (PI3K), colony-stimulating factor-1 receptor (CSF1R), and tyrosine kinase non-receptor 2 (TNK2, also known as ACK1). Here, TNK2 is linked to posterior cortical atrophy.